Data gathered: December 25
AI Stock Analysis - Dexcom (DXCM)
Analysis generated October 7, 2024. Powered by Chat GPT.
Dexcom, Inc. is a market leader in continuous glucose monitoring (CGM) systems for diabetes management. Founded in 1999 and headquartered in San Diego, California, Dexcom has focused on developing and marketing CGM devices for people with diabetes. The company's flagship product, the Dexcom G6, allows users to monitor their glucose levels in real time without the need for fingersticks. As a company that operates in the healthcare and medical technology sector, Dexcom is well-positioned to benefit from the increasing prevalence of diabetes worldwide and the shift towards more advanced, patient-friendly monitoring solutions.
Stock Alerts - Dexcom (DXCM)
 |
Dexcom | December 20 Price is up by 5.3% in the last 24h. |
|
Dexcom | December 18 Insider Alert: Stern Sadie is selling shares |
|
Dexcom | November 25 Price is up by 6% in the last 24h. |
|
Dexcom | November 23 Insider Alert: Stern Sadie is selling shares |
Alternative Data for Dexcom
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 221 | Sign up | Sign up | Sign up |
| Sentiment | 90 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,799,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | 42 | Sign up | Sign up | Sign up |
| Patents | 804 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 17,160 | Sign up | Sign up | Sign up |
| Facebook Followers | 194,747 | Sign up | Sign up | Sign up |
| Instagram Followers | 175,521 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 7 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 9,901 | Sign up | Sign up | Sign up |
| Twitter Followers | 8,863 | Sign up | Sign up | Sign up |
| Twitter Mentions | 20 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 41,000 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | 32 | Sign up | Sign up | Sign up |
| Business Outlook | 70 | Sign up | Sign up | Sign up |
| Linkedin Employees | 7,297 | Sign up | Sign up | Sign up |
About Dexcom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
| Price | $80.24 |
| Target Price | Sign up |
| Volume | 979,370 |
| Market Cap | $31.3B |
| Year Range | $64 - $138.01 |
| Dividend Yield | 0% |
| PE Ratio | 48.63 |
| Analyst Rating | 83% buy |
| Industry | Medical Devices |
In the news
Abbott Agrees to Global Continuous Glucose Monitoring Litigation Settlement with DexcomDecember 23 - Finnhub |
|
 |
AI-Powered Glucose Monitors - The Dexcom GenAI Platform Has a Proprietary Profile (TrendHunter.com)December 23 - Trendhunter.com |
 |
DexCom (DXCM) Soars 5.6%: Is Further Upside Left in the Stock?December 22 - Yahoo |
 |
Sanctuary Advisors LLC Has $1.08 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)December 22 - ETF Daily News |
DEXCOM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of DexCom, Inc. - DXCMDecember 20 - Finnhub |
|
|
Orion Portfolio Solutions LLC Cuts Stake in DexCom, Inc. (NASDAQ:DXCM)December 20 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 994M | 707M | 594M | 135M | 237M | 0.450 |
| Q2 '24 | 1B | 710M | 627M | 144M | 245M | 0.430 |
| Q1 '24 | 916M | 678M | 562M | 146M | 190M | 0.320 |
| Q4 '23 | 1.03B | 696M | 657M | 256M | 261M | 0.500 |
| Q3 '23 | 970M | 638M | 623M | 121M | 247M | 0.500 |
Insider Transactions View All
| Leach Jacob Steven filed to sell 264,171 shares at $76.9. December 17 '24 |
| Sylvain Jereme M filed to sell 80,030 shares at $76.9. December 17 '24 |
| Stern Sadie filed to sell 70,768 shares at $76.9. December 17 '24 |
| Heller Bridgette P filed to sell 23,349 shares at $76.9. December 17 '24 |
| Stern Sadie filed to sell 71,192 shares at $74.7. November 22 '24 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Boston ScientificBSX |
$91.11 0% | 48 |
 |
Edwards LifesciencesEW |
$75.69 0% | 33 |
 |
Intuitive SurgicalISRG |
$537.36 0% | 76 |
 |
MedtronicMDT |
$81.54 0% | 49 |
 |
StrykerSYK |
$370.78 0% | 50 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Ro Khanna |
Oct 8, 24 | Buy | $1K - $15K |
| Rohit Khanna Democrat |
Nov 8, 23 | Buy | $1K - $15K |
| Rohit Khanna Democrat |
Nov 8, 23 | Buy | $1K - $15K |
Read more about Dexcom (DXCM) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Dexcom?
The Market Cap of Dexcom is $31.3B.
What is Dexcom's PE Ratio?
As of today, Dexcom's PE (Price to Earnings) ratio is 48.63.
What is the current stock price of Dexcom?
Currently, the price of one share of Dexcom stock is $80.24.
How can I analyze the DXCM stock price chart for investment decisions?
The DXCM stock price chart above provides a comprehensive visual representation of Dexcom's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Dexcom shares. Our platform offers an up-to-date DXCM stock price chart, along with technical data analysis and alternative data insights.
Does DXCM offer dividends to its shareholders?
As of our latest update, Dexcom (DXCM) does not offer dividends to its shareholders. Investors interested in Dexcom should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Dexcom?
Some of the similar stocks of Dexcom are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.
.